Although most cervical human papillomavirus type 16 (HPV16) infections become
undetectable within 1–2 years, persistent HPV16 causes half of all cervical cancers. We …

Background Testing for human papillomavirus (HPV) is being incorporated into the cervical
screening programme, with the probable future introduction of HPV as a primary test and a …

E6 oncoprotein is a necessary agent of HPV driven oncogenic transformation. This study is
aimed at evaluating the risk stratification potency of HPV 16/18 E6 oncoprotein (E6) as a …

A challenge in implementation of sensitive HPV‐based screening is limiting unnecessary
referrals to colposcopic biopsy. We combined two commonly recommended triage methods …

Background Human papillomavirus (HPV) vaccination is still not reaching many high-risk
populations. HPV16/18 vaccines offer cross-protection against other types, for example …

Histological low-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia
grade 1 (LSIL/CIN1) preceded by normal or mildly abnormal cytology is recommended for …

Background This study evaluated the intra‐and inter‐observer reproducibility of the dual‐
stain biomarker, CIN tec® PLUS cytology in ThinPrep® specimens, for improved specificity …

Only a small proportion of women who are exposed to infection with high-risk human
papillomavirus (HR-HPV) progress to persistent infection and develop cervical cancer (CC) …

Persistence of high-risk human papillomavirus (HPV) represents the necessary cause of
cervical cancer. Researching natural history of HPV infection is important to identify high-risk …

Testing negative for human papillomavirus (HPV) predicts long‐term reassurance against
invasive cervical cancer (ICC). To provide realistic estimates of effectiveness for new …